Looking to expand your partner network with leading companies like Silence Therapeutics? Consider joining Inpart's global network for free.
In Depth 22 Jul 2022
The coming of age story of RNAi technology
The first RNA interference (RNAi) therapy was approved in 2018, after 20 years in development. What can we expect to see in the RNAi field in the future? After two decades of scientific effort, multiple devastating clinical trial setbacks, and billions of dollars spent on research and development, RNAi therapies are finally establishing themselves in […]
